Study
Prevagen®: Analysis of Clinical Evidence and Its Designation as a “#1 Pharmacist Recommended Brand”
A 2022 review assessed Prevagen’s available studies, highlighting methodological weaknesses and lack of independent replication.
Summary
In plain language
A critical analysis of the clinical evidence supporting Prevagen, a popular memory supplement containing apoaequorin, examining the quality and findings of published research on its cognitive benefits.
Details
Use the full description to understand the study design, methods, and the limits of the findings.
This analysis reviews the clinical research underlying Prevagen's claims for memory and cognitive support. The paper evaluates study methodologies, outcomes, and regulatory designations to provide an evidence-based assessment of this widely marketed brain health supplement.
Full Study
Open the original publication for the complete methods, outcomes, and source material.
Prevagen®: Analysis of Clinical Evidence and Its Designation as a “#1 Pharmacist Recommended Brand”
Published December 2025
Opens at the publisher · external site · may require institutional access
Research Quality Score
Scored February 1, 2026 using rubric v6_2026-02-01.
Assessment
The study provides a critical analysis of existing clinical research on Prevagen, focusing on methodological quality and regulatory designations. While it offers valuable insights, it does not conduct new research or statistical analyses, limiting its evidence level. The study is relevant to seniors, given its focus on cognitive health supplements marketed to this demographic.
Category Breakdown
| Category | Score | Rating |
|---|---|---|
| Study design | 6.0/10 | |
| Bias control | 5.0/10 | |
| Statistical methods | 6.0/10 | |
| Reporting completeness | 7.0/10 | |
| Conflicts & funding | 8.0/10 | |
| Replication | 5.0/10 | |
| Relevance to chosen population | 7.0/10 | |
| Journal Reliability | 7.0/10 |
Additional Notes
The study's strength lies in its critical evaluation of existing evidence rather than generating new data. It is useful for understanding the current landscape of research on Prevagen but should be interpreted with caution due to its secondary nature.
Treatments Evaluated in This Research
Review the interventions studied here and compare them against the broader treatment library.
Take the next step
Build a personalized plan using research-backed studies, conditions, and treatments.